A novel PPARgamma agonist monascin's potential application in diabetes prevention

Wei-Hsuan Hsu, Tzu Ming Pan

Research output: Contribution to journalReview article

12 Citations (Scopus)

Abstract

Edible fungi of the Monascus species have been used as traditional Chinese medicine in eastern Asia for several centuries. Monascus-fermented products possess a number of functional secondary metabolites, including the anti-inflammatory pigments monascin and ankaflavin. Monascin has been shown to prevent or ameliorate several conditions, including hypercholesterolemia, hyperlipidemia, diabetes, and obesity. Recently, monascin has been shown to improve hyperglycemia, attenuate oxidative stress, inhibit insulin resistance, and suppress inflammatory cytokine production. In our recent study, we have found that monascin is a peroxisome proliferator-activated receptor-gamma (PPARgamma) agonist. The PPARgamma agonist activity had been investigated and its exerted benefits are inhibition of inflammation in methylglyoxal (MG)-treated rats, prevention of pancreas impairment causing advanced glycation endproducts (AGEs), promotion of insulin expression in vivo and in vitro, and attenuated carboxymethyllysine (CML)-induced hepatic stellate cell (HSC) activation in the past several years. Moreover, our studies also demonstrated that monascin also activated nuclear factor-erythroid 2-related factor 2 (Nrf2) in pancreatic RIN-m5F cell line thereby invading methylglyoxal induced pancreas dysfunction. In this review, we focus on the chemo-preventive properties of monascin against metabolic syndrome through PPARgamma and Nrf2 pathways. This journal is

Original languageEnglish
Pages (from-to)1334-1340
Number of pages7
JournalFood and Function
Volume5
Issue number7
DOIs
Publication statusPublished - 2014 Jan 1

Fingerprint

PPAR gamma
Monascus
agonists
diabetes
pancreas
ankaflavin
edible fungi
Pyruvaldehyde
hypercholesterolemia
metabolic syndrome
hyperlipidemia
hyperglycemia
East Asia
insulin resistance
secondary metabolites
Pancreas
medicine
obesity
cytokines
oxidative stress

All Science Journal Classification (ASJC) codes

  • Food Science

Cite this

@article{ba9b1f111f8949fc9b6ab1246b728978,
title = "A novel PPARgamma agonist monascin's potential application in diabetes prevention",
abstract = "Edible fungi of the Monascus species have been used as traditional Chinese medicine in eastern Asia for several centuries. Monascus-fermented products possess a number of functional secondary metabolites, including the anti-inflammatory pigments monascin and ankaflavin. Monascin has been shown to prevent or ameliorate several conditions, including hypercholesterolemia, hyperlipidemia, diabetes, and obesity. Recently, monascin has been shown to improve hyperglycemia, attenuate oxidative stress, inhibit insulin resistance, and suppress inflammatory cytokine production. In our recent study, we have found that monascin is a peroxisome proliferator-activated receptor-gamma (PPARgamma) agonist. The PPARgamma agonist activity had been investigated and its exerted benefits are inhibition of inflammation in methylglyoxal (MG)-treated rats, prevention of pancreas impairment causing advanced glycation endproducts (AGEs), promotion of insulin expression in vivo and in vitro, and attenuated carboxymethyllysine (CML)-induced hepatic stellate cell (HSC) activation in the past several years. Moreover, our studies also demonstrated that monascin also activated nuclear factor-erythroid 2-related factor 2 (Nrf2) in pancreatic RIN-m5F cell line thereby invading methylglyoxal induced pancreas dysfunction. In this review, we focus on the chemo-preventive properties of monascin against metabolic syndrome through PPARgamma and Nrf2 pathways. This journal is",
author = "Wei-Hsuan Hsu and Pan, {Tzu Ming}",
year = "2014",
month = "1",
day = "1",
doi = "10.1039/c3fo60575b",
language = "English",
volume = "5",
pages = "1334--1340",
journal = "Food and Function",
issn = "2042-6496",
publisher = "Royal Society of Chemistry",
number = "7",

}

A novel PPARgamma agonist monascin's potential application in diabetes prevention. / Hsu, Wei-Hsuan; Pan, Tzu Ming.

In: Food and Function, Vol. 5, No. 7, 01.01.2014, p. 1334-1340.

Research output: Contribution to journalReview article

TY - JOUR

T1 - A novel PPARgamma agonist monascin's potential application in diabetes prevention

AU - Hsu, Wei-Hsuan

AU - Pan, Tzu Ming

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Edible fungi of the Monascus species have been used as traditional Chinese medicine in eastern Asia for several centuries. Monascus-fermented products possess a number of functional secondary metabolites, including the anti-inflammatory pigments monascin and ankaflavin. Monascin has been shown to prevent or ameliorate several conditions, including hypercholesterolemia, hyperlipidemia, diabetes, and obesity. Recently, monascin has been shown to improve hyperglycemia, attenuate oxidative stress, inhibit insulin resistance, and suppress inflammatory cytokine production. In our recent study, we have found that monascin is a peroxisome proliferator-activated receptor-gamma (PPARgamma) agonist. The PPARgamma agonist activity had been investigated and its exerted benefits are inhibition of inflammation in methylglyoxal (MG)-treated rats, prevention of pancreas impairment causing advanced glycation endproducts (AGEs), promotion of insulin expression in vivo and in vitro, and attenuated carboxymethyllysine (CML)-induced hepatic stellate cell (HSC) activation in the past several years. Moreover, our studies also demonstrated that monascin also activated nuclear factor-erythroid 2-related factor 2 (Nrf2) in pancreatic RIN-m5F cell line thereby invading methylglyoxal induced pancreas dysfunction. In this review, we focus on the chemo-preventive properties of monascin against metabolic syndrome through PPARgamma and Nrf2 pathways. This journal is

AB - Edible fungi of the Monascus species have been used as traditional Chinese medicine in eastern Asia for several centuries. Monascus-fermented products possess a number of functional secondary metabolites, including the anti-inflammatory pigments monascin and ankaflavin. Monascin has been shown to prevent or ameliorate several conditions, including hypercholesterolemia, hyperlipidemia, diabetes, and obesity. Recently, monascin has been shown to improve hyperglycemia, attenuate oxidative stress, inhibit insulin resistance, and suppress inflammatory cytokine production. In our recent study, we have found that monascin is a peroxisome proliferator-activated receptor-gamma (PPARgamma) agonist. The PPARgamma agonist activity had been investigated and its exerted benefits are inhibition of inflammation in methylglyoxal (MG)-treated rats, prevention of pancreas impairment causing advanced glycation endproducts (AGEs), promotion of insulin expression in vivo and in vitro, and attenuated carboxymethyllysine (CML)-induced hepatic stellate cell (HSC) activation in the past several years. Moreover, our studies also demonstrated that monascin also activated nuclear factor-erythroid 2-related factor 2 (Nrf2) in pancreatic RIN-m5F cell line thereby invading methylglyoxal induced pancreas dysfunction. In this review, we focus on the chemo-preventive properties of monascin against metabolic syndrome through PPARgamma and Nrf2 pathways. This journal is

UR - http://www.scopus.com/inward/record.url?scp=84903276524&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903276524&partnerID=8YFLogxK

U2 - 10.1039/c3fo60575b

DO - 10.1039/c3fo60575b

M3 - Review article

C2 - 24752777

AN - SCOPUS:84903276524

VL - 5

SP - 1334

EP - 1340

JO - Food and Function

JF - Food and Function

SN - 2042-6496

IS - 7

ER -